Referencer

1.
Singh-Manoux A et al (2011). Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ; 343:d7622 doi: 10.1136/bmj.d7622.

2.
Ryan L et al (2002). Caffeine reduces time-of-day effects on memory performance in older adults. Psychol Sci;13:68-71.

3.
Smith AP (1994). Caffeine, performance, mood and status of reduced alertness. Pharmacopsychoecologia;7:75-86.

4.
Smith AP (2005). Caffeine. In Nutritional Neuroscience, Lieberman H, Kanarek R, Prasad C, eds. Taylor & Francis, Boca Raton, FL;pp. 335-359.

5.
Swift CG & Tiplady B (1988). The effects of age on the response to caffeine. Psychopharmacology (Berl);94:29-31.

6.
Rees K et al (1999). The influences of age and caffeine on psychomotor and cognitive function. Psychopharmacology (Berl);145:181-188.

7.
Hogervorst E et al (1998). Caffeine improves memory performance during distraction in middle-aged, but not in young or old subjects. Hum Psychopharmacol;13:277-284.

8.
Lorist MM et al (1995). Aging, caffeine, and information processing: an event-related potential analysis. Electroencephalogr Clin Neurophysiol;96:453-467.

9.
Jarvis MJ (1993). Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology;110:45-52.

10.
Hameleers PA et al (2000). Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol;15:573-581.

11.
van Hooren SA et al (2005). Influence of cognitive functioning on functional status in an older population: 3- and 6-year follow-up of the Maastricht Aging Study. Int J Geriatr Psychiatry;20:883-888.

12.
Cropley V et al (2011). Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study. Psychopharmacology (Berl); 219(3):737-49.

13.
Santos C et al (2010). Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis;20 Suppl 1:S187-204.

14.
Johnson-Kozlow M et al (2002). Coffee consumption and cognitive function among older adults. Am J Epidemiol;156:842-850.

15.
Ritchie K et al (2007). The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology;69:536-545.

16.
Santos C et al (2010). Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal. J Alzheimers Dis;20 Suppl 1:S175-85.

17.
Arab L et al (2011). Gender Differences in Tea, Coffee, and Cognitive Decline in the Elderly: The Cardiovascular Health Study. J Alzheimers Dis. Aug 12. [Epub ahead of print]

18.
van Gelder BM et al (2007). Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr;61:226-32.

19.
Corley J et al (2010). Caffeine consumption and cognitive function at age 70: The Lothian birth cohort 1936 study. Psychosom Med;72:206-14.

20.
Wu MS et al (2011). Socio-demographic and health-related factors associated with cognitive impairment in the elderly in Taiwan. BMC Public Health;11:22.

21.
Alzheimer Europe (2010). Alzheimer’s disease.

22.
Alzheimer Europe (2009). Who is affected by Alzheimer’s disease?

23.
Alzheimer Europe (2010). The impact of Alzheimer’s disease in Europe.

24.
Maia L & de Mendonça A (2002). Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol;9:377-82.

25.
Lindsay J et al (2002). Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol;156:445-53.

26.
Broe GA et al (1990). A case-control study of Alzheimer’s disease in Australia. Neurology;40:1698-707.

27.
Tyas SL et al (2001). Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol;30:590-7.

28.
Barranco Quintana JL et al (2007). Alzheimer’s disease and coffee: a quantitative review. Neurol Res;29:91-5.

29.
Lammi UK et al (1989). Mental disability among elderly men in Finland: prevalence, predictors and correlates. Acta Psychiatr Scand;80:459-68.

30.
Eskelinen MH et al (2009). Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis;16:85-91.

31.
Laitala VS et al (2009). Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr;90:640-6.

32.
Gelber RP et al (2011). Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis;23:607-15.

33.
Arendash GW et al (2006). Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience;142:941-52.

34.
Arendash GW et al (2009). Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimers Dis;17:661-80.

35.
Cao C et al (2009). Caffeine suppresses amyloid-β levels in plasma and brain of Alzheimer’s disease transgenic mice. J Alzheimers Dis;17:681-97.

36.
Cao C et al (2011). Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. J Alzheimers Dis; 25(2):323-35.

37.
Han ME et al (2009). Regulation of cerebrospinal fluid production by caffeine consumption. BMC Neurosci;10:110.

38.
Wostyn P et al (2011). Increased cerebrospinal fluid production as a possible mechanism underlying caffeine’s protective effect against Alzheimer’s disease. Int J Alzheimers Dis;2011:617420.

39.
Tohda C et al (2005). Search for natural products related to regeneration of the neuronal network. Neurosignals;14:34-45.

40.
Tohda C et al (1999). Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells. Biol Pharm Bull;22:679-82.

41.
Kim HS et al (2004). Inhibitory effects of long-term administration of ferulic acid on microglial activation induced by intracerebroventricular injection of beta-amyloid peptide (1-42) in mice. Biol Pharm Bull;27:120-1.

42.
Cho JY et al (2005). Inhibitory effects of long-term administration of ferulic acid on astrocyte activation induced by intracerebroventricular injection of beta-amyloid peptide (1-42) in mice. Prog Neuropsychopharmacol Biol Psychiatry;29:901-7.

43.
European Parkinson’s Disease Association (2011). EPDA Annual report 2010-2011.

44.
European Parkinson’s Disease Association (2011). Life with Parkinson’s.

45.
Nefzger MD et al (1968). A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol; 88:149-158.

46.
Jimenez-Jimenez FJ et al (1992). Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord; 7:339-44.

47.
Fall PA et al (1999). Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov Disord; 14:28-37.

48.
Hellenbrand W et al (1996). Diet and Parkinson’s disease. I. A possible role for the past intake of specific foods. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology;47:636-43.

49.
Webster Ross G et al (2000). Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA; 283:2674-2679.

50.
Hernan MA et al (2002). A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol;52:276-84.

51.
Costa J et al (2010). Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis;20 Suppl 1:S221-38.

52.
Ascherio A et al (2001). Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol;50:56-63.

53.
Ascherio A et al (2003). Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology;60:790-5.

54.
Palacios N et al (2010). Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson’s disease in men and women. Parkinsonism Relat Disord;16:370-5.

55.
Kuwana Y et al (1999). Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Adv Neurol, 80:121-3.

56.
Fenu S & Morelli M (1998). Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors. Eur J Neurosci;10:1878-84.

57.
Chen JF et al (2001). Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci;21:RC143.

58.
Morelli M et al (2009). Adenosine A2A receptors and Parkinson’s disease. Handb Exp Pharmacol;193:589-615.

59.
Iida M et al (1999). Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res; 838:51-9.

60.
WHO World Health Report – 2002.

61.
Larsson SC et al (2008). Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke;39:1681-7.

62.
Larsson SC et al (2011). Coffee consumption and risk of stroke in women. Stroke;42:908-12.

63.
Lopez-Garcia E et al (2009). Coffee consumption and risk of stroke in women. Circulation;119:1116-23.

64.
Larsson SC & Orsini N (2011). Coffee consumption and risk of stroke: A dose-response meta-analysis of prospective studies. Am J Epidemiol; Sep 13. [Epub ahead of print]

65.
Piriyawat P et al (2003). Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke;34:1242-5.